2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Insulin Receptor

Insulin Receptor

Insulin Receptor

Related Products

PDF 0.56 MB

Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.

The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P3577
    [Tyr0] Gastric Inhibitory Peptide (23-42), human
    [Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research.
    [Tyr0] Gastric Inhibitory Peptide (23-42), human
  • HY-P5433F
    IRS-1 Peptide, FAM labeled
    		Substrate
    IRS-1 Peptide, FAM labeled is a biological active peptide. (Insulin receptor substrate)
    IRS-1 Peptide, FAM labeled
  • HY-P5291
    CPF-7
    CPF-7 (Caerulein precursor fragment) is an insulin-releasing peptide that stimulates the release of insulin. CPF-7 can induce epithelial-mesenchymal transition by upregulating Snai1 expression in PANC-1 ductal cells. CPF-7 also induces exocrine plasticity by upregulating Ngn3 expression. CPF-7 can be used in the research of type 2 diabetes.
    CPF-7
  • HY-101758
    BM-131246
    BM-131246 is an oral antidiabetic agent.
    BM-131246
  • HY-P1901
    Insulin alpha-chain (1-13)
    Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain.
    Insulin alpha-chain (1-13)
  • HY-112469
    ERK Inhibitor II (Negative control)
    		Inhibitor
    ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes.
    ERK Inhibitor II (Negative control)
  • HY-P991290
    IRAB-B
    		Antagonist
    IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes.
    IRAB-B
  • HY-153479
    Aganirsen
    		Inhibitor
    Aganirsen is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).
    Aganirsen
  • HY-19176
    S-15261
    		Activator
    S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome.
    S-15261
  • HY-P1773
    IGF-I (30-41)
    IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).
    IGF-I (30-41)
  • HY-103545
    GIP (1-39)
    		Agonist
    GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca2+ concentration ([Ca2+]i), and capable of enhancing exocytosis.
    GIP (1-39)
  • HY-138842
    DDN
    		Activator
    DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice.
    DDN
  • HY-19960R
    BCTC (Standard)
    		Agonist
    BCTC (Standard) is the analytical standard of BCTC. This product is intended for research and analytical applications. BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
    BCTC (Standard)
  • HY-13203R
    NVP-TAE 226 (Standard)
    		Inhibitor
    NVP-TAE 226 (Standard) is the analytical standard of NVP-TAE 226. This product is intended for research and analytical applications. NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively.
    NVP-TAE 226 (Standard)
  • HY-15656R
    Ceritinib (Standard)
    		Inhibitor
    Ceritinib (Standard) is the analytical standard of Ceritinib. This product is intended for research and analytical applications. Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib (LDK378) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency.
    Ceritinib (Standard)
  • HY-10191R
    Linsitinib (Standard)
    		Inhibitor
    Linsitinib (Standard) is the analytical standard of Linsitinib. This product is intended for research and analytical applications. Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively.
    Linsitinib (Standard)
  • HY-P990867
    Anti-CD220/Insulin Receptor Antibody (IR 83-22)
    Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to human CD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-CD220/Insulin Receptor Antibody (IR 83-22)
  • HY-14243
    CEP-14083
    		Inhibitor
    CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC50 value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma.
    CEP-14083
  • HY-W516943
    CI-624
    		Inhibitor
    CI-624 decrease secretion volumes and outputs of hydrogen, sodium and potassium ions and of pepsin. CI-624 can be used in the research of cancer and autoimmune diseases.
    CI-624
  • HY-15656AR
    Ceritinib dihydrochloride (Standard)
    		Inhibitor
    Ceritinib dihydrochloride (Standard) is the analytical standard of Ceritinib dihydrochloride. This product is intended for research and analytical applications. Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib dihydrochloride (LDK378 dihydrochloride) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride (LDK378 dihydrochloride) shows great antitumor potency.
    Ceritinib dihydrochloride (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity